ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: conducted a prospective trial in 40 patients with CML‐CP and showed a higher incidence of TFR in patients with undetectable BCR::ABL1 DNA; however, the difference was not statistically significant.26